132491-90-8Relevant academic research and scientific papers
Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor
Sliedregt, Leo A. J. M.,Rensen, Patrick C. N.,Rump, Erik T.,Van Santbrink, Peter J.,Bijsterbosch, Martin K.,Valentijn, A. Rob P. M.,Van Der Marel, Gijs A.,Van Boom, Jacques H.,Van Berkel, Theo J. C.,Biessen, Erik A. L.
, p. 609 - 618 (1999)
A series of glycolipids have been prepared which contain a cluster galactoside moiety with high affinity for the hepatic asialoglycoprotein receptor and a bile acid ester moiety which mediates stable incorporation into liposomes. Loading of liposomes with
Selective targeting of DC-SIGN by controlling the oligomannose pattern on a polyproline tetra-helix macrocycle scaffold
Wen, Hsin-Chuan,Lin, Cin-Hao,Huang, Jen-Sheng,Tsai, Chia-Lung,Chen, Ting-Feng,Wang, Sheng-Kai
, p. 9124 - 9127 (2019)
DC-SIGN and langerin receptors both bind to oligomannose but lead to opposite effects upon encountering HIV. Because selective targeting of DC-SIGN can lead to anti-viral effects, we developed a glycoconjugate, which provides over 4800-fold selectivity for DC-SIGN over langerin, by controlling the oligomannose pattern on a polyproline tetra-helix macrocycle scaffold.
Neutral highly branched metallomacromolecules: Incorporation of a (2,2':6',2'-terpyridine) ruthenium(II) complex without external counterions
Newkome, George R.,He, Enfei,Godinez, Luis A.,Baker, Gregory R.
, p. 27 - 28 (1999)
Neutral dendritic metallomacromolecules possessing four bis-terpyridine Ru(II) linking sites with internal counter ions have been prepared and their electrochemical properties have been studied.
Receptor-Specific Delivery of Peptide Nucleic Acids Conjugated to Three Sequentially Linked N-Acetyl Galactosamine Moieties into Hepatocytes
Bhingardeve, Pramod,Madhanagopal, Bharath Raj,Naick, Hemanth,Jain, Prashant,Manoharan, Muthiah,Ganesh, Krishna
supporting information, p. 8812 - 8824 (2020/08/14)
Peptide nucleic acids (PNAs) are DNA analogs that bind with high affinity to DNA and RNA in a sequence-specific manner but have poor cell permeability, limiting use as therapeutic agents. The work described here is motivated by recent reports of efficient gene silencing specifically in hepatocytes by small interfering RNAs conjugated to triantennary N-acetyl galactosamine (GalNAc), the ligand recognized by the asialoglycoprotein receptor (ASGPR). PNAs conjugated to either triantennary GalNAc at the N-terminus (the branched architecture) or monomeric GalNAc moieties anchored at Cγ of three consecutive PNA monomers of N-(2-aminoethyl)glycine (aeg) scaffolds (the sequential architecture) were synthesized on the solid phase. These formed duplexes with complementary DNA and RNA as shown by UV and circular dichroism spectroscopy. The fluorescently labeled analogs of GalNAc-conjugated PNAs were internalized by HepG2 cells that express the ASGPR but were not taken up by HEK-293 cells that lack this receptor. The sequential conjugate was internalized about 13-fold more efficiently than the branched conjugate into HepG2 cells, as demonstrated by confocal microscopy. The results presented here highlight the potential significance of the architecture of GalNAc conjugation for efficient uptake by target liver cells and indicate that GalNAc-conjugated PNAs have possible therapeutic applications.
TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE
-
Page/Page column 112, (2015/04/15)
Provided herein are compounds comprising one or more therapeutic nucleosides and one or more targeting groups. In certain embodiments, the compounds further comprise one or more oligonucleotides. In certain embodiments, a targeting group comprises one or more N-Acetylgalactosamine.
COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
-
Page/Page column 176-178, (2016/01/26)
Provided herein are compositions and methods for non-parenteral delivery of conjugated oligomeric compounds. In certain embodiments, compositions and methods are provided for oral delivery of conjugated oligomeric compounds. In certain embodiments, the ol
COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
-
Page/Page column 154, (2015/11/23)
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
-
Page/Page column 146, (2015/11/23)
The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (GHR).
COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
-
Page/Page column 179, (2015/11/23)
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
-
Page/Page column 511, (2014/11/13)
Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
